Literature DB >> 30228113

Higher Activity of Alcohol Dehydrogenase Is Correlated with Hepatic Fibrogenesis.

Na Gao1, Jing Li1, Ming-Rui Li1, Bing Qi1, Zhao Wang1, Gao-Ju Wang1, Jie Gao1, Hai-Ling Qiao2.   

Abstract

Hepatofibrosis can progress to cirrhosis and hepatocellular carcinoma (HCC). Prevention, stabilization, and reversal of disease progression are vital for patients with hepatofibrosis, and identifying the risk factors for hepatofibrosis is urgently needed. In this study, we examined the activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) in the fibrotic livers of HCC patients (n = 88) and comparied these results with activities in patients with normal livers (n = 74). A fibrosis-carcinoma rat model was used to study the activity of ADH in fibrosis and HCC and the relationship between innate ADH activity and the extent of hepatofibrosis or HCC. Substantial interindividual variations were found in the activities of ADH and ALDH in normal livers. The activity levels of total ADH, ADHI, and ADHII in fibrotic livers were significantly higher than those in normal livers (P < 0.001), whereas the activity of ALDH was slightly greater. The positive rates of ADHI and ADHII were 84.1% and 77.3%, respectively; the areas under the receiver operator characteristics (ROC) curve were 0.943 and 0.912, respectively. For the rat model compared with controls, ADH activity in liver was significantly increased at the fibrotic and HCC stages, and no significant difference was noted between ADH activity in the liver at these two stages. The innate activity of ADH in serum was well correlated with the extent of hepatofibrosis as indicated by Masson area%, Ki67+%, proliferating cell nuclear antigen +%, and GST-p average density at fibrotic stage but not at HCC stage. A higher level of activity of ADH is a risk factor for hepatofibrogenesis and might be a prevention target for hepatofibrosis.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30228113     DOI: 10.1124/jpet.118.249425

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Effects of Gene Polymorphisms, Metabolic Activity, and Content of Alcohol Dehydrogenase and Acetaldehyde Dehydrogenases on Prognosis of Hepatocellular Carcinoma Patients.

Authors:  Na Gao; Jingjing Chen; Bing Qi; Tianyuan Zhao; Yuanyuan Guo; Yan Fang; Zixinying Han; Hai-Ling Qiao
Journal:  Turk J Gastroenterol       Date:  2022-07       Impact factor: 1.555

2.  Comprehensive Analysis of Aldehyde Dehydrogenases (ALDHs) and Its Significant Role in Hepatocellular Carcinoma.

Authors:  Senbang Yao; Wenjun Chen; He Zuo; Ziran Bi; Xiuqing Zhang; Lulian Pang; Yanyan Jing; Xiangxiang Yin; Huaidong Cheng
Journal:  Biochem Genet       Date:  2021-12-20       Impact factor: 2.220

3.  Prognostic implications of alcohol dehydrogenases in hepatocellular carcinoma.

Authors:  Xiangye Liu; Tingting Li; Delong Kong; Hongjuan You; Fanyun Kong; Renxian Tang
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.430

Review 4.  Aldehyde Dehydrogenase, Liver Disease and Cancer.

Authors:  Wenjun Wang; Chunguang Wang; Hongxin Xu; Yanhang Gao
Journal:  Int J Biol Sci       Date:  2020-01-22       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.